



July 15, 2021 - December 1, 2021
Diabetes Mellitus
On-demand Encore Virtual Session

ACTIVITY OVERVIEW

On-demand Encore Virtual Sessions consist of recorded CE accredited sessions from the live meeting.

Diabetes Mellitus affects 34 million people in the United States and is the leading cause of kidney failure, acquired blindness, and non-traumatic amputations in this country. Type 1 Diabetes is an autoimmune disease in which the immune system destroys pancreatic beta cells resulting in absolute insulin deficiency, while the pathophysiology of type 2 diabetes involves a complex interplay between excessive hepatic glucose production, tissue insulin resistance, and insulin deficiency. Maintaining good glucose control can prevent the chronic complications of diabetes. Several diabetes medications have also been shown to have highly beneficial effects on co-morbidities such as cardiovascular disease, heart failure and chronic kidney disease. Case discussions will be used to illustrate personalized decision making regarding glycemic targets and therapeutic choices for individual diabetes patients.

TARGET AUDIENCE

This educational initiative is intended for Nurse Practitioners, Nurses, Primary Care Physicians and Physician assistants.

LEARNING OBJECTIVES

- Review the pathophysiology of Type 1 and Type 2 Diabetes Mellitus and where diabetes medications exert their actions.
- Describe the effectiveness, benefits and risks of currently available therapeutic options for treating type 2 Diabetes Mellitus.
- Use case discussions to illustrate personalized decision making regarding glycemic targets and therapeutic choices for individual diabetes patients through case discussions.

CRITERIA FOR SUCCESS

To obtain a certificate of completion, a score of 80% or better on the post-test is required. Please proceed with the activity until you have successfully completed this program, completed the post-test and evaluation, and have received a digital copy of your certificate. You must participate in the entire activity to receive credit. If you have questions about this activity, please contact AKH Inc. at kwolynski@akhcme.com

Please claim credit by December 31, 2021.



Credit provided by AKH, Inc., Advancing Knowledge in Healthcare



JOINTLY ACCREDITED PROVIDER
INTERPROFESSIONAL CONTINUING EDUCATION

In support of improving patient care, this activity has been planned and implemented by AKH Inc., Advancing Knowledge in Healthcare and National Nurse Practitioner Symposium. AKH Inc., Advancing Knowledge in Healthcare is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physicians

AKH Inc., Advancing Knowledge in Healthcare designates this enduring material activity for a maximum of 1.5 *AMA PRA Category 1 Credit(s)*[™]. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses

Credit being awarded 1.5 ANCC contact hours



AAPA Credit Designation Statement

AKH Inc., Advancing Knowledge in Healthcare has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.5 AAPA Category 1 CME credits. Approval is valid until 12/31/2021. PAs should only claim credit commensurate with the extent of their participation.



This activity has been planned and implemented in accordance with the Accreditation Standards of the American Association of Nurse Practitioners (AANP) through the joint providership of AKH Inc., Advancing Knowledge in Healthcare and National Nurse Practitioner Symposium. AKH Inc., Advancing Knowledge in Healthcare is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number: 030803. This activity is approved for 1.5 contact hour(s) (which includes 1.125 hour(s) of pharmacology).

Commercial Support

This activity is supported by an educational funding from AstraZeneca Pharmaceuticals and Amgen.

Disclosure

It is the policy of AKH Inc. to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. The author must disclose to the participants any significant relationships with ineligible companies whose products or devices may be mentioned in the activity or with the commercial supporter of this continuing education activity. Identified conflicts of interest are mitigated by AKH prior to accreditation of the activity. AKH planners and reviewers have no relevant financial relationships to disclose.

| FACULTY / PLANNERS / REVIEWER DISCLOSURES | | |
|---|--------------|---|
| NAME | RELATIONSHIP | COMPANY |
| Michael T. McDermott, MD | Consultant | Novo Nordisk Advisory Board, United Health Group Advisory Board |
| Dorothy Caputo, MA, BSN, RN - CE Director of Accreditations | N/A | Nothing to disclose |
| Bernadette Marie Makar, MSN, NP-C, APRN-C- BC- Nurse Planner | N/A | Nothing to disclose |
| NNPS Planners and Reviewers | N/A | Nothing to disclose |
| AKH Planners and Reviewers | N/A | Nothing to disclose |
| All of the relevant financial relationships listed for these individuals have been mitigated. | | |

Disclosure of Unlabeled Use and Investigational Product

This educational activity may include discussion of uses of agents that are investigational and/or unapproved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

This course is designed solely to provide the healthcare professional with information to assist in his/her practice and professional development and is not to be considered a diagnostic tool to replace professional advice or treatment. The course serves as a general guide to the healthcare professional, and therefore, cannot be considered as giving legal, nursing, medical, or other professional advice in specific cases. AKH Inc. specifically disclaim responsibility for any adverse consequences resulting directly or indirectly from information in the course, for undetected error, or through participant's misunderstanding of the content.